AstraZeneca and G42 Healthcare, an AI-powered healthcare company, have signed a strategic partnership agreement to locally manufacture drugs in Abu Dhabi. The binding agreement focuses on collaboration in four key areas including localizing innovative industries, research and development, innovation and sustainability at a global scale, the companies said in a statement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca says PEARL trial didn’t achieve statistical significance on endpoint
- AstraZeneca says Imfinzi plus Imjudo recommended for approval in EU by CHMP
- AstraZeneca reports Enhertu approved in EU for previously treated gastric cancer
- AstraZeneca reports Forxiga recommended for extend indication in EU by CHMP
- AstraZeneca, Daiichi Sankyo announce Enhertu recommended for approval in the EU